Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Andrew Östör, Eugen Feist, Prodromos Sidiropoulos, Jérôme Avouac, Martin Rebella, Rajaie Namas, Erin McDearmon-Blondell, Tianming Gao, Ivan Lagunes-Galindo, Sander Strengholt, Devy Zisman, Suzan Attar

Open source

DOI: 10.1186/s13075-025-03528-5
Published: 2025-04-10
Container: Arthritis Research & Therapy
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13075-025-03528-5,
  title = {Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study},
  author = {Andrew Östör and Eugen Feist and Prodromos Sidiropoulos and Jérôme Avouac and Martin Rebella and Rajaie Namas and Erin McDearmon-Blondell and Tianming Gao and Ivan Lagunes-Galindo and Sander Strengholt and Devy Zisman and Suzan Attar},
  year = {2025},
  journal = {Arthritis Research \&amp; Therapy},
  doi = {10.1186/s13075-025-03528-5},
  url = {https://doi.org/10.1186/s13075-025-03528-5}
}

RIS

TY  - JOUR
TI  - Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study
AU  - Andrew Östör
AU  - Eugen Feist
AU  - Prodromos Sidiropoulos
AU  - Jérôme Avouac
AU  - Martin Rebella
AU  - Rajaie Namas
AU  - Erin McDearmon-Blondell
AU  - Tianming Gao
AU  - Ivan Lagunes-Galindo
AU  - Sander Strengholt
AU  - Devy Zisman
AU  - Suzan Attar
PY  - 2025
JO  - Arthritis Research &amp; Therapy
DO  - 10.1186/s13075-025-03528-5
UR  - https://doi.org/10.1186/s13075-025-03528-5
ER  -

APA

Östör, A., Feist, E., Sidiropoulos, P., Avouac, J., Rebella, M., Namas, R., McDearmon-Blondell, E., Gao, T., Lagunes-Galindo, I., Strengholt, S., Zisman, D., & Attar, S. (2025). Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-025-03528-5

Source records

crossref · retrieved 2026-09-25T21:02:05.497Z